novain
agepha pharma s.r.o - oksibuprokaino hidrochloridas - akių lašai (tirpalas) - 4 mg/ml - oxybuprocaine
kinzalmono (previously telmisartan boehringer ingelheim pharma kg)
bayer ag - telmisartan - hipertenzija - renino ir angiotenzino sistemos veikiantys vaistai - hypertensiontreatment esminių hipertenzija suaugusiems. Širdies ir kraujagyslių preventionreduction širdies ir kraujagyslių negalavimų turintiems pacientams:manifestą atherothrombotic širdies ir kraujagyslių ligos (istorija, išeminė širdies liga, insultas arba periferinių arterijų liga); arba 2 tipo cukrinis diabetas su dokumentais tikslą-organų pažeidimo.
altiva
sun pharmaceutical industries europe b. v. - feksofenadinas - plėvele dengtos tabletės - 120 mg; 180 mg - fexofenadine
balmedil
pharmaswiss Česká republika s.r.o. - paracetamolis/feniramino maleatas/askorbo rūgštis - granulės geriamajam tirpalui - 500 mg/25 mg/200 mg - paracetamol, combinations excl. psycholeptics
dorzolamide/timolol teva
teva pharma b.v. - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
ketanov
sun pharmaceutical industries europe b. v. - ketorolako trometamolis - injekcinis tirpalas - 30 mg/ml - ketorolac
vanatex hct
zakłady farmaceutyczne polpharma s.a. - valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 160 mg/25 mg; 160 mg/12,5 mg; 80 mg/12,5 mg - valsartan and diuretics
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antinavikiniai vaistai - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
ontozry
angelini pharma s.p.a - cenobamate - epilepsija - antiepileptics, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antinavikiniai vaistai - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.